Phase III studies of a gene therapy for Leber hereditary optic neuropathy have generated some unexpected positive findings. There is biologic plausibility to explain the data, according to Robert C. Sergott, MD.
Josh Mali, MD, shares how AbbVie’s recent financial takeover rattles up the ophthalmic space, and what this means for future pharmaceutical acquisitions.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
